SOA Wealth Advisors LLC. Sells 222 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

SOA Wealth Advisors LLC. lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 22.0% during the second quarter, Holdings Channel.com reports. The fund owned 789 shares of the financial services provider’s stock after selling 222 shares during the period. SOA Wealth Advisors LLC.’s holdings in iShares Biotechnology ETF were worth $100,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of IBB. Vigilant Capital Management LLC bought a new position in iShares Biotechnology ETF in the first quarter valued at approximately $26,000. WealthPLAN Partners LLC acquired a new stake in shares of iShares Biotechnology ETF in the 1st quarter valued at approximately $27,000. Thompson Investment Management Inc. bought a new position in shares of iShares Biotechnology ETF in the first quarter valued at $38,000. Red Lighthouse Investment Management LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter worth $39,000. Finally, Lakewood Asset Management LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter worth $39,000. Institutional investors own 69.61% of the company’s stock.

iShares Biotechnology ETF Trading Down 0.8 %

Shares of IBB stock opened at $126.61 on Friday. The company has a fifty day moving average price of $128.08 and a two-hundred day moving average price of $129.36. iShares Biotechnology ETF has a one year low of $113.37 and a one year high of $138.74.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.